Related Experiment Videos
Therapeutic cancer vaccines based on molecularly defined human tumor antigens
Pedro Romero1, Mikael Pittet, Valerie Dutoit
1Divison of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Avenue Pierre-Decker 4, 1005 Lausanne, Switzerland. pedro.romero@isrec.unil.ch
Abstract:
The results of numerous phases I and II clinical trials testing the safety and immunogenicity of various cancer vaccine formulations based on cytolytic T lymphocytes (CTLs)-defined tumor antigens have been reported recently. Specific T cell responses can be detected in only a fraction of immunized patients. A smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites.
Insights
Recent cancer vaccine trials show limited T cell responses and tumor regressions. Effective therapeutic vaccination needs to enhance natural anti-tumor immunity and maintain functional T cells at tumor sites.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Numerous Phase I and II clinical trials have investigated cancer vaccine safety and immunogenicity.
- Vaccines are based on cytolytic T lymphocytes (CTLs)-defined tumor antigens.
- Current cancer vaccines show variable success in eliciting specific T cell responses.
Purpose of the Study:
- To evaluate the outcomes of recent clinical trials on cancer vaccines.
- To identify key factors for successful therapeutic cancer vaccination.
- To understand the relationship between T cell response and tumor regression.
Main Methods:
- Review of Phase I and II clinical trial data.
- Analysis of immunogenicity and safety profiles of various cancer vaccine formulations.
- Assessment of T cell responses and objective tumor responses in immunized patients.
Main Results:
- Only a fraction of patients exhibit detectable specific T cell responses after vaccination.
- A smaller subset of these patients demonstrate objective tumor responses.
- The efficacy of cancer vaccines varies significantly across patient populations.
Conclusions:
- Current cancer vaccine strategies show limited clinical efficacy.
- Boosting naturally occurring anti-tumor responses is crucial for effective vaccination.
- Sustaining tumor antigen-specific, functional effector T cells at tumor sites is essential for therapeutic success.